

Edgar Filing: BRAINSTORM CELL THERAPEUTICS INC - Form 8-K

BRAINSTORM CELL THERAPEUTICS INC
Form 8-K
December 29, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) December 28, 2004

BrainStorm Cell Therapeutics Inc.
(Exact name of registrant as specified in its charter)

Washington	333-61610	912061053
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

36 Derech Bait Lechem
Jerusalem, Israel 77002
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code 011-972-2-6737445

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02(D) APPOINTMENT OF NEW DIRECTORS

On December 28, 2004 our Board of Directors increased its size from two to three directors and appointed Mr. Michael Greenfield (Ben-Ari) to serve as a director.

Edgar Filing: BRAINSTORM CELL THERAPEUTICS INC - Form 8-K

Since 1997, Mr. Greenfield (Ben-Ari), age 45, has served as manager of Evergreen Field Enterprises, his own consulting company, where he specializes in investment consulting and portfolio management. From 1991 to 1997, Mr. Greenfield (Ben-Ari) served as Vice President of Marketing at Bank Leumi. Mr. Greenfield holds an MBA from Tel-Aviv University and a BA from Brandeis University.

Mr. Greenfield (Ben-Ari) is not a party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404 of Regulation S-B.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 28, 2004

BRAINSTORM CELL THERAPEUTICS, INC.

/s/ Yaffa Beck

Name: Yaffa Beck

Title: President & CEO